EMA Revoked: Dimethyl fumarate Polpharma (dimethyl fumarate) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

View source ↗

Summary

EMA revoked the Dimethyl fumarate Polpharma product, a therapy for relapsing-remitting multiple sclerosis, indicating withdrawal of authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Dimethyl fumarate Polpharma (dimethyl fumarate)

Snippet

Status: Revoked. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.. Decision date: 13/12/2023